Androgen deprivation therapy (ADT) for prostate carcinoma (PCa) may cause cardiometa- bolic complications unless intermittent androgen blockade (IAB) is instituted. An 80-year-old caucasian man was diagnosed intermediate grade (Gleason 4 + 3) PCa and was treated with continuous ADT with triptorelin plus bicalutamide. After 6 months of treatment, he experienced an acute myocardial infarction and 1 month after hospitalization he came to our outpatient clinic for fatigue, weight gain, and hyperglycemia. Due to iatrogenic hypogonadism, we decided to proceed with IAB, but after 3 months ADT withdrawal his serum testosterone (T) was still 0.5 ng/mL. Due to very low concomitant PSA levels (0.1 ng/mL) he was then proposed intermittent T-gel supplementation (Tostrex®) which was initiated according to the following scheme: 6 months on and 3 months off. T-gel dose was titrated tri-weekly in order to achieve T plasma levels below 3.49 ng/mL. After 6 months on, his serum T raised to a mean value of about 2.0 ng/mL without increments in PSA. After overall 12 months on, his serum T peaked to a mean value of 3.0 ng/mL while a delay in PSA rise was seen after 24 months (0.6 ng/mL) but remained stable until the last observation carried forward (LOCF), at 45 months. No clinical and biochemical PCa progression were observed at LOCF. Reversion of iatrogenic metabolic syndrome started after 6 months of T supplementation without using any add-on treatment. This case provides support that once regression of PCa growth is attained,T supplementation may be administered in well differentiated PCa, especially if IAB is not successful in reverting iatrogenic hypogonadism and its associated cardiac and metabolic complications. © 2012 Aversa, Francomano and Lenzi.

Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: Effects of 3 years intermittent testosterone supplementation / Aversa, Antonio; Francomano, Davide; Lenzi, Andrea. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - ELETTRONICO. - 3:FEB(2012), p. 17. [10.3389/fendo.2012.00017]

Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: Effects of 3 years intermittent testosterone supplementation

AVERSA, Antonio;FRANCOMANO, DAVIDE;LENZI, Andrea
2012

Abstract

Androgen deprivation therapy (ADT) for prostate carcinoma (PCa) may cause cardiometa- bolic complications unless intermittent androgen blockade (IAB) is instituted. An 80-year-old caucasian man was diagnosed intermediate grade (Gleason 4 + 3) PCa and was treated with continuous ADT with triptorelin plus bicalutamide. After 6 months of treatment, he experienced an acute myocardial infarction and 1 month after hospitalization he came to our outpatient clinic for fatigue, weight gain, and hyperglycemia. Due to iatrogenic hypogonadism, we decided to proceed with IAB, but after 3 months ADT withdrawal his serum testosterone (T) was still 0.5 ng/mL. Due to very low concomitant PSA levels (0.1 ng/mL) he was then proposed intermittent T-gel supplementation (Tostrex®) which was initiated according to the following scheme: 6 months on and 3 months off. T-gel dose was titrated tri-weekly in order to achieve T plasma levels below 3.49 ng/mL. After 6 months on, his serum T raised to a mean value of about 2.0 ng/mL without increments in PSA. After overall 12 months on, his serum T peaked to a mean value of 3.0 ng/mL while a delay in PSA rise was seen after 24 months (0.6 ng/mL) but remained stable until the last observation carried forward (LOCF), at 45 months. No clinical and biochemical PCa progression were observed at LOCF. Reversion of iatrogenic metabolic syndrome started after 6 months of T supplementation without using any add-on treatment. This case provides support that once regression of PCa growth is attained,T supplementation may be administered in well differentiated PCa, especially if IAB is not successful in reverting iatrogenic hypogonadism and its associated cardiac and metabolic complications. © 2012 Aversa, Francomano and Lenzi.
2012
testosterone gel; myocardial infarction; metabolic syndrome; localized prostate cancer
01 Pubblicazione su rivista::01a Articolo in rivista
Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: Effects of 3 years intermittent testosterone supplementation / Aversa, Antonio; Francomano, Davide; Lenzi, Andrea. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - ELETTRONICO. - 3:FEB(2012), p. 17. [10.3389/fendo.2012.00017]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/436815
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 7
  • ???jsp.display-item.citation.isi??? ND
social impact